Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214811 · ClinicalTrials.gov registry record · Phase 3
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
A Phase 3 study of Inflammation and Burns, sponsored by Molnlycke Health Care AB.
- Completed
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
- 3
- Study locations
NCT01214811 is a Phase 3 study of Inflammation and Burns that has completed, run by Molnlycke Health Care AB. The registered enrollment target is 27 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01214811, a Phase 3 study of Inflammation and Burns, has completed, sponsored by Molnlycke Health Care AB.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the change in signs of inflammation/local infection when Mepilex Border Ag is used in normal clinical practice when used on chronic ulcers (venous leg, diabetic foot and pressure ulcers) and partial thickness burns in need\* of topical antimicrobial treatment according to the physician.
Conditions Studied
Interventions
- DEVICE Mepilex Border Ag
Study Locations (3)
Alabama
- Institute for advanced wound care - Momtgomery
Iowa
- Burn treatment center - Iowa City
New York
- Center for Curative & Palliative Care, Calvary Hospital - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01214811
The ClinicalTrials.gov registry entry for NCT01214811 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (91% lower). The listed sponsor is Molnlycke Health Care AB, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Mepilex Border Ag is the first listed.
NCT01214811 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Iowa, New York.
Frequently Asked Questions
What is clinical trial NCT01214811 about?
NCT01214811 is a clinical study titled "Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing". The purpose of this study is to evaluate the change in signs of inflammation/local infection when Mepilex Border Ag is used in normal clinical practice when used on chronic ulcers (venous leg, diabetic foot and pressure ulcers) and partial thickness burns in need\* of topical antimicrobial treatment...
What is the current status of trial NCT01214811?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2010-09. Estimated completion is 2011-12.
What conditions does trial NCT01214811 study?
This clinical trial studies the following conditions: Inflammation, Burns, Ulcers.
What interventions are being tested in trial NCT01214811?
The interventions under investigation include: Mepilex Border Ag (DEVICE).
Who is sponsoring clinical trial NCT01214811?
This trial is sponsored by Molnlycke Health Care AB, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01214811 being conducted?
This trial has 3 study locations across Alabama, Iowa, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RECRUITING · Phase 3
-
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
COMPLETED · Phase 3
-
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
COMPLETED · Phase 3
-
A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery
COMPLETED · Phase 3
-
Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.